{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269573","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.133627+00:00","generated_at":"2026-05-16T23:47:12.602689+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tectonic Q3 net loss $19M; positive TX45 Phase 1b data in PH-HFrEF","bullets":["Net loss of $19.0M in Q3 2025 vs $17.7M in Q3 2024; R&D expenses $16.9M.","Cash and equivalents $268.4M as of Sept 30, 2025; runway into Q4 2028.","TX45 Part B: 29.2% reduction in PCWP, 17.3% improvement in cardiac output in PH-HFrEF.","TX45 APEX Phase 2 in PH-HFpEF over 50% enrolled; topline results expected in 2026.","TX2100 Phase 1 for HHT to start Q1 2026; TX45 PH-ILD Phase 2 planned in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269573","json":"https://secwatch.observer/filing/0001193125-25-269573.json","markdown":"https://secwatch.observer/filing/0001193125-25-269573.md","text":"https://secwatch.observer/filing/0001193125-25-269573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525269573/0001193125-25-269573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525269573/tecx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:47:12.602689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}